Dr. Du studies inherited and modifiable predictors of cancer, with a focus on colorectal, endometrial, and pancreatic cancers. This work, carried out in collaboration with international research teams, seeks to understand tumorigenesis and identify individuals who could most benefit from targeted lifestyle modifications or preventive interventions. She is an investigator in the Genetics and Epidemiology of Colorectal Cancer Consortium, where she and a cross disciplinary team of researchers study the interplay of genetic and modifiable factors in colorectal cancer. With colleagues in the African Research Group in Oncology, she is carrying out a pilot study in Nigeria to shed light on the unique risk factor profile and biology of colorectal cancers in this understudied population. Dr. Du leads the MSK coordinating center and serves on the Executive Committee of the Epidemiology of Endometrial Cancer Consortium, where she and colleagues study endometrial cancer risk factors and plan to expand to risk prediction and tissue collection efforts. Dr. Du recently assumed co-leadership of the MSK Pancreatic Tumor Registry founded by Drs. Sara Olson and Robert Kurtz. The registry team has enrolled patients with pancreatic cancer or with intraductal papillary mucinous neoplasms and is actively conducting follow-up and surveillance of at-risk unaffected relatives. The registry also contributes to the Pancreatic Cancer Case-Control Consortium, in which Dr. Du is a collaborator in ongoing genetic studies, including an NCI-funded project to validate and fine-map pancreatic cancer susceptibility loci. In addition, Dr. Du studies telomere dynamics in the Nurses’ Health Study, a large nationwide cohort of women’s health. She serves on the Scientific Committee for the New York City Epidemiology Forum and is an Associate Editor for the international journal Cancer Causes & Control.